9 Jul 2021 08:30
9 July 2021
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings and Issue of Equity
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the issue and allotment of 973,682 ordinary shares of £0.05 under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), including 679,768 new Shares to persons discharging managerial responsibilities ("PDMR").
PDMR Total number of New Nature of issuance
Ordinary Shares issued
Martin Whitaker 376,230 Vesting of deferred bonus award
Richard Bungay 225,738 Vesting of deferred bonus award
Richard Ross 77,800 Vesting of deferred bonus award
The shares were issued under the Company's Employee Benefit Trust scheme.
Martin Whitaker and Richard Bungay have informed the Company that they intend to sell sufficient shares to pay all or part of their personal tax liability arising from the vesting of their deferred bonus awards once the New Ordinary Shares have been admitted for trading on AIM and will retain the balance of shares. These transactions will be subject to a further RNS announcement in due course.
Following the issue of shares, the total beneficial interest of Martin Whitaker and his connected parties is 980,053 Ordinary Shares, representing 0.58% of the total voting rights, the total beneficial interest of Richard Bungay is 339,990 Ordinary Shares, representing 0.20% of the total voting rights, and the total beneficial interest of Richard Ross and his connected parties is 2,262,155 Ordinary Shares, representing 1.34% of the total voting rights.
Application has been made for admission of the 973,682 New Ordinary Shares to trading on AIM, which is anticipated to occur at 8:00am on Monday 12 July 2021 ("Admission"). The New Ordinary Shares will rank pari passu with the existing shares of common stock of the Company. Following Admission, the Company's issued ordinary share capital will consist of 168,903,690 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 168,903,690.
The above figure of 168,903,690 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Details of the full notifications received by the Company are set out below:
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Martin Whitaker | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
|
| ||||
Identification code | GB00BDB6Q760 | ||||
|
| ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
| Nil | 376,230 |
| |
|
|
|
|
| |
d)
| Aggregated information |
| |||
|
| ||||
- Aggregated volume | As above | ||||
|
| ||||
- Price |
| ||||
|
| ||||
e)
| Date of the transaction
| 9 July 2021 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Richard Bungay | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Financial Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
|
| ||||
Identification code | GB00BDB6Q760 | ||||
|
| ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
| Nil | 225,738 |
| |
|
|
|
|
| |
d)
| Aggregated information |
| |||
|
| ||||
- Aggregated volume | As above | ||||
|
| ||||
- Price |
| ||||
|
| ||||
e)
| Date of the transaction
| 9 July 2021 | |||
f)
| Place of the transaction
| XLON | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Richard Ross | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Scientific Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Diurnal Group plc | |||
b)
| LEI
| 213800I2HNUNZN1LDH29 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
|
| ||||
Identification code | GB00BDB6Q760 | ||||
|
| ||||
b)
| Nature of the transaction
| Acquisition of ordinary shares
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
| Nil | 77,800 |
| |
|
|
|
|
| |
d)
| Aggregated information |
| |||
|
| ||||
- Aggregated volume | As above | ||||
|
| ||||
- Price |
| ||||
|
| ||||
e)
| Date of the transaction
| 9 July 2021 | |||
f)
| Place of the transaction
| XLON | |||
For further information, please visit www.diurnal.co.uk or contact: | |
|
|
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer |
|
Richard Bungay, Chief Financial Officer |
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl |
|
Corporate Broking: Rupert Dearden |
|
|
|
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway |
|
Victoria Foster Mitchell |
|
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
DNL.L (DNL)